Firendia 20 mg (Tablet)
Unit Price: ৳ 150.00 (3 x 10: ৳ 4,500.00)
Strip Price: ৳ 1,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Reduce risk of sustained eGFR decline
- Reduce risk of end-stage kidney disease
- Reduce risk of cardiovascular death
- Reduce risk of nonfatal myocardial infarction
- Reduce risk of hospitalization for heart failure
- For adult patients with CKD associated with T2D
Pharmacology
- Nonsteroidal
- Selective antagonist of mineralocorticoid receptor
- Blocks MR mediated sodium reabsorption
- No relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
- High potency and selectivity for MR
- Completely absorbed after oral administration
- Metabolized by CYP3A4 and CYP2C8
Dosage & Administration
- Recommended starting dosage of 10 mg or 20 mg orally once daily
- Increase dosage to target dose of 20 mg once daily after 4 weeks
- Dosage based on eGFR and serum potassium thresholds
- Tablets can be taken with or without food
- Dosage adjustments based on serum potassium levels
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Monitor serum potassium with moderate or weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Hyperkalemia
- Hypotension
- Hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Animal studies showed developmental toxicity
- Avoid breastfeeding during treatment and for 1 day after
Precautions & Warnings
- Risk of hyperkalemia
- Measure serum potassium and eGFR before initiation
- Do not initiate if serum potassium is > 5.0 mEq/L
- Monitor serum potassium periodically
- More frequent monitoring for high-risk patients
Use in Special Populations
- No established safety and efficacy in patients below 18 years of age
- 58% of patients in FIDELIO-DKD study were 65 years and older
- Avoid use in patients with severe hepatic impairment
- No dose adjustment in geriatric patients 65 years and older
Overdose Effects
- Immediately interrupt treatment in case of suspected overdose
- Manifestation of overdose is typically hyperkalemia
- Standard treatment for hyperkalemia
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Store below 30°C temperature
- Keep away from light and moisture
- Keep out of reach of children